Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Bayer Yakuhin Logs Double-Digit Growth for 2 Years Running on Xarelto
April 8, 2015
-
BUSINESS Drug Makers Setting Up Medical Affairs Units Independent of Sales Teams
April 7, 2015
-
ORGANIZATION JPMA to Closely Watch Clinical Research Bill to Decide Whether to Review All Ads
April 6, 2015
-
BUSINESS Sanofi Japan Sales Dip 7.6% on Generic Erosion though Plavix Grew
April 3, 2015
-
ACADEMIA Stop Use of SGLT-2 Inhibitors, NSAIDs in Elderly: Japan Geriatrics Society
April 3, 2015
-
BUSINESS Mochida Unveils New 3-Year Biz Targets, Price Revisions, Generic Penetration Weigh
April 2, 2015
-
BUSINESS Lupin Group’s Kyowa Sees Japan-India Collaboration as Key to Survival: Pres.
April 1, 2015
-
ACADEMIA CRPC Drugs Xtandi, Zytiga Neck-and-Neck in Key Opinion Leader Poll
April 1, 2015
-
BUSINESS Fujifilm to Buy US iPS Cell Manufacturer Cellular Dynamics
March 31, 2015
-
REGULATORY Otani, Ex-Number 2 at MHLW, Tapped as Aide to Chief of AMED
March 30, 2015
-
BUSINESS Pfizer Looking for Drug Discovery Partnerships with Domestic Drug Makers
March 30, 2015
-
REGULATORY Nonpartisan Group Launched to Push Biosimilar Use, Lawmaker-Sponsored Bill Eyed
March 27, 2015
-
BUSINESS Sovaldi, Oral, Interferon-Free Treatment, Approved for Chronic HCV Infection in Japan: Gilead Sciences
March 27, 2015
-
ORGANIZATION Applying Uniform Pricing Rule to Unprofitable but Essential Drugs Difficult: Kenporen Veep
March 26, 2015
-
BUSINESS 3-Bracket Pricing Rule for Generics Should Be Defended: Sawai Chairman
March 25, 2015
-
BUSINESS Takeda to Collaborate with ImmunoGen for ADC Technology
March 25, 2015
-
BUSINESS AZ Looks to Lead Industry in Immuno-Oncology Arena: Oncology Head
March 24, 2015
-
INTERVIEW Takeda Aims to Return to Growth Track in FY2016, Sales Head Confident in Takecab
March 23, 2015
-
BUSINESS Amgen Astellas Seeks Japan Approval of PCSK9 Inhibitor
March 23, 2015
-
ORGANIZATION FPMAJ Renews Call for Changing NHI Pricing Rules for Unprofitable Drugs with Great Medical Needs
March 20, 2015
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…